AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Shares of AbbVie Inc. ABBV inched 0.35% higher to $193.62 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie Inc . (NYSE:ABBV) Executive Chairman of the Board, Richard A. Gonzalez, has recently sold a significant number of shares in the company. According to the latest filings, ...

The stock market “can’t win” at the moment, said Andrew Brenner, head of international fixed income at National Alliance Securities. “Heads I lose, tails I lose.” Data delayed at least ...